Viridian Therapeutics to Report First Quarter 2022 Financial Results and Host Conference Call on May 12, 2022
May 03 2022 - 7:00AM
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company
advancing new treatments for patients suffering from serious
diseases underserved by current therapies, today announced it will
report its financial results from the first quarter ended March 31,
2022, after the financial markets close on Thursday, May 12,
2022.
The Company’s management team is scheduled to host a conference
call at 4:30 p.m. ET on Thursday, May 12, 2022. To
access the call, please dial 1-877-270-2148 in
the U.S. or 1-412-902-6510 outside the U.S. and
ask for the Viridian call. To access the live webcast, please visit
the “Events” page in the Investors section of the Viridian
Therapeutics, Inc. website. Following the live webcast, an archived
version of the call will be available on the website.
Thursday, May 12 @ 4:30 p.m.
ET
Domestic: |
1-877-270-2148 |
International: |
1-412-902-6510 |
Webcast: |
Webcast Link |
About Viridian Therapeutics
Viridian Therapeutics is a biotechnology company advancing
new treatments for patients suffering from serious diseases but
underserved by today’s therapies. Viridian’s most advanced program,
VRDN-001, is a differentiated monoclonal antibody targeting
insulin-like growth factor-1 receptor (IGF-1R), a clinically and
commercially validated target for the treatment of thyroid eye
disease (TED). Viridian’s second product candidate, VRDN-002, is a
distinct anti-IGF-1R antibody that incorporates half-life extension
technology and is designed to support administration as a
convenient, low-volume, subcutaneous injection. TED is a
debilitating autoimmune disease that causes inflammation and
fibrosis within the orbit of the eye which can cause double vision,
pain, and potential blindness. Patients with severe disease often
require multiple remedial surgeries to the orbit, eye muscles and
eyelids. Viridian is based in Waltham, Massachusetts.
Investor and Media Contact:John JordanViridian
TherapeuticsVice President, Investor Relations& Corporate
Communications617-272-4691IR@viridiantherapeutics.com
Viridian Therapeutics (NASDAQ:VRDN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Viridian Therapeutics (NASDAQ:VRDN)
Historical Stock Chart
From Jul 2023 to Jul 2024